Milestone Pharmaceuticals Plans To Resubmit The NDA For Etripamil To FDA For Paroxysmal Supraventricular Tachycardia
Portfolio Pulse from Benzinga Newsdesk
Milestone Pharmaceuticals plans to resubmit the NDA for Etripamil to the FDA for Paroxysmal Supraventricular Tachycardia after addressing concerns from a Refusal to File letter. The FDA indicated that the timing of adverse events had minimal impact on the safety profile of Etripamil, and the company will restructure and reformat data sets for resubmission.
February 26, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Milestone Pharmaceuticals is set to resubmit the NDA for Etripamil, addressing FDA's concerns, which could positively impact the company's prospects.
The resubmission of the NDA for Etripamil represents a significant step towards potential approval. The FDA's feedback that the timing of adverse events has minimal impact on the drug's safety profile is positive news. This development is likely to be viewed favorably by investors, potentially leading to a short-term positive impact on MIST's stock price.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100